Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal recessive cutis laxa type I that has material basis in homozygous or compound heterozygous mutation in the FBLN5 gene on chromosome 14q32.
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Features include always present findings: Abnormal cutaneous elastic fiber morphology, Cutis laxa, Redundant skin, and Emphysema and others; and common findings: Inguinal hernia, Low muscle tone (hypotonia), Premature sagging cheeks, and Peripheral pulmonary artery stenosis and others. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 3 | Emphysema, Peripheral pulmonary artery stenosis, Recurrent respiratory infections |
Heart and blood vessels | 2 | Supravalvular aortic stenosis, Aortic regurgitation |
Skin | 2 | Hyperextensible skin, Redundant skin |
Muscles | 1 | Low muscle tone (hypotonia) |
Pregnancy and birth | 1 | Congenital diaphragmatic hernia |
Head and neck | 1 | Microcephaly |
Kidneys and urinary system | 1 | Ascending tubular aorta aneurysm |
Bones and joints | 1 | Joint hypermobility |
Blood and immune system | 1 | Recurrent respiratory infections |
Age of onset: at birth.
To date, six families with autosomal recessive FBLN5-related cutis laxa have been described [, , , , , , ]. Intrafamilial variability in age of onset is observed. Cutis laxa. The most common finding in FBLN5-related cutis laxa is described as furrowing of the skin of the whole body that is particularly obvious in the neck, axillae, and groin. The face has a "droopy" appearance with eyelid ptosis and drooping cheeks. When one tries to extend the skin, it does not display hyperelasticity as in the Ehlers-Danlos syndromes, but rather keeps its consistency. Pulmonary emphysema. Most affected individuals have early childhood-onset pulmonary emphysema, and some individuals have presented with emphysema during the neonatal period.
Source: GeneReviews — "FBLN5-Related Cutis Laxa"
FBLN5 encodes fibulin 5 (448 aa). Essential for elastic fiber formation, is involved in the assembly of continuous elastin (ELN) polymer and promotes the interaction of microfibrils and ELN. Highest expression in Artery Aorta (795.1 TPM) and Cells Cultured fibroblasts (292.3 TPM).
Cutis laxa, autosomal recessive, type 1A is associated with mutations in the FBLN5 gene on chromosome 14.
The FBLN5 protein participates in Tropoelastin associates with microfibrils pathway.
FBLN5 is classified as a druggable target (Druggable Genome category) with score 0.0.
FBLN5-related cutis laxa should be suspected in individuals with the following clinical features:
Cutis laxa
Pulmonary emphysema
Arterial involvement (e.g., peripheral pulmonary artery stenosis, supravalvar aortic stenosis)
Inguinal hernias
Hollow viscus diverticula (e.g., intestine, bladder)
Pyloric stenosis
The diagnosis of FBLN5-related cutis laxa is established in a proband with the above and biallelic pathogenic (or likely pathogenic) variants in FBLN5 (autosomal recessive FBLN5-related cutis laxa) or a heterozygous pathogenic (or likely pathogenic) variant in FBLN5 (autosomal dominant FBLN5-related cutis laxa) identified by molecular genetic testing .
Source: GeneReviews — "FBLN5-Related Cutis Laxa"
Other disorders characterized by cutis laxa are summarized in . EFEMP2-related cutis laxa (ARCL1B). EFEMP2-related cutis laxa is characterized by cutis laxa and systemic involvement, most commonly arterial tortuosity, aneurysms, and stenosis; retrognathia; joint laxity; and arachnodactyly. Severity ranges from perinatal lethality as a result of cardiopulmonary failure to manifestations limited to the vascular and craniofacial systems. The cutis laxa and emphysema are similar in FBLN4- or FBLN5-related cutis laxa; however, to date, the diaphragmatic changes and arterial aneurysms seem more predominant in EFEMP2-related cutis laxa. ATP6V0A2-related cutis laxa (ARCL2A) spans a phenotypic spectrum that includes Debr-type cutis laxa at the severe end and wrinkly skin syndrome at the mild end.
Source: GeneReviews — "FBLN5-Related Cutis Laxa"
Genetic testing for FBLN5 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for cutis laxa, autosomal recessive, type 1A. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with FBLN5-related cutis laxa, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with FBLN5-Related Cutis Laxa
System/Concern | Evaluation | Comment |
|---|---|---|
Cardiovascular | Echocardiogram | Consider pulmonary vessel angiogram if clinically indicated. |
Renal | Kidney ultrasound exam | Consider voiding cystoureterogram, given potential presence of urethral diverticula; catheterization should be done carefully. IV pyelogram may be an alternative. |
Gastrointestinal | Exam for inguinal hernia | Barium enema if clinically indicated |
Other | Consultation w/clinical geneticist /or genetic counselor | IV = intravenous Treatment of Manifestations Table 4. Treatment of Manifestations in Individuals with FBLN5-Related Cutis Laxa Manifestation/Concern |
Source: GeneReviews — "FBLN5-Related Cutis Laxa"
1 trial found
Routine surveillance of the urinary tract for evidence of bladder diverticula and/or vesicoureteral reflux is indicated.
Source: GeneReviews — "FBLN5-Related Cutis Laxa"
Phenotype severity distribution: 5 always present features, 5 common features.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
4 publications have been identified in PubMed for cutis laxa, autosomal recessive, type 1A. Research spans Case Report / Case Series (100%).
Teixeira J (2025). [PMID: 40194804](https://pubmed.ncbi.nlm.nih.gov/40194804/). *BMJ case reports*. [Case Report / Case Series]
Sikhayeva N (2025). [PMID: 41300699](https://pubmed.ncbi.nlm.nih.gov/41300699/). *Genes (Basel)*. [Case Report / Case Series]
Abdullah M (2024). [PMID: 36728588](https://pubmed.ncbi.nlm.nih.gov/36728588/). *Retinal cases & brief reports*. [Case Report / Case Series]
Georgeos MKH (2024). [PMID: 39544917](https://pubmed.ncbi.nlm.nih.gov/39544917/). *F1000Res*. [Case Report / Case Series]